Compare NOC & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOC | TAK |
|---|---|---|
| Founded | 1939 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.9B | 59.8B |
| IPO Year | 2002 | 2007 |
| Metric | NOC | TAK |
|---|---|---|
| Price | $553.00 | $20.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 3 |
| Target Price | ★ $619.08 | $22.77 |
| AVG Volume (30 Days) | 900.6K | ★ 2.5M |
| Earning Date | 10-20-2026 | 10-29-2026 |
| Dividend Yield | 1.79% | ★ 2.42% |
| EPS Growth | ★ 2.61 | N/A |
| EPS | ★ 21.72 | N/A |
| Revenue | ★ $41,954,000,000.00 | N/A |
| Revenue This Year | $4.99 | $4.40 |
| Revenue Next Year | $6.63 | $1.95 |
| P/E Ratio | ★ $25.49 | $41.25 |
| Revenue Growth | ★ 2.24 | N/A |
| 52 Week Low | $471.36 | $12.99 |
| 52 Week High | $774.00 | $20.39 |
| Indicator | NOC | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 68.38 | 70.39 |
| Support Level | $519.35 | $17.58 |
| Resistance Level | $560.42 | N/A |
| Average True Range (ATR) | 12.54 | 0.28 |
| MACD | 9.34 | 0.17 |
| Stochastic Oscillator | 96.19 | 94.46 |
Northrop Grumman is a diversified defense contractor providing aeronautics, defense, and space systems. The company's aerospace segment produces autonomous and piloted aircraft such as Global Hawk drones and the B-21 bomber, creates the fuselage for the massive F-35 program, and maintains and upgrades numerous other military aircraft. Defense systems makes artillery and missile ammunition and guidance systems, long-range missiles, and missile defense systems. Mission systems creates and integrates a variety of radar, navigation, and communication systems for avionics, weapons control, and countermeasures on a range of platforms from helicopters to destroyers. Space systems produces satellites, sensors, space structures, and rocket motors.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.